



NDA 20-479/S-005

Celltech Pharmaceuticals
755 Jefferson Road
P.O. Box 31710
Rochester, NY 14603-1710

Attention: Cheryl Rini
Senior Manager, Regulatory Affairs

Dear Ms. Rini:

Please refer to your supplemental new drug application dated August 22, 2002, received August 23, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Gastrocrom (cromolyn sodium, USP) Oral Concentrate.

This "Changes Being Effected" supplemental new drug application proposes the addition of a Geriatric Use subsection to the PRECAUTIONS section of the package insert.

We have completed our review of this application and it is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the submitted labeling (package insert submitted August 22, 2002).

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-479/S-005." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Colette Jackson, Project Manager, at (301) 827-5584.

Sincerely,

{See appended electronic signature page}

Badrul A. Chowdhury, MD, Ph.D.
Acting Director
Division of Pulmonary and Allergy Drug Products, HFD-570
Office of Drug Evaluation II
Center For Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Badrul Chowdhury
2/13/03 03:55:22 PM